Faron Pharmaceuticals has raised €12 million in a share placing, beating its €10 million target after strong investor demand. The funds will support ongoing trials of bexmarilimab, its experimental cancer immunotherapy.
Researchers at the University of New Mexico have made a breakthrough in understanding how cancer spreads using ANGLE’s Parsortix system. They found that tumour cells cluster with immune B cells, making them harder to detect and more likely to spread.
Meanwhile, Ananda Pharma has appointed Andy Rust as a commercial adviser to help bring its cannabinoid drugs to market. Rust has 30 years of experience in pharmaceuticals, including senior roles in pain management and respiratory medicine.
And BenevolentAI is asking shareholders to approve delisting from Euronext Amsterdam as part of a cost-cutting overhaul. The board says staying public no longer makes financial sense, and the money saved will go towards AI-driven drug development.
In mining news, Andrada Mining has updated its resource estimates for the Uis mine in Namibia, covering the V1V2 pegmatite. The company says this is another step towards becoming a major African producer of tin, lithium, and tantalum.
